Revista de Senologia y Patologia Mamaria最新文献

{"title":"How can we integrate current adjuvant treatment options in triple negative patients with residual disease after neoadjuvant treatment?","authors":"Mª. Teresa Quintanar-Verdúguez ,&nbsp;María Ballester Espinosa ,&nbsp;Javier Pérez-Altozano ,&nbsp;Álvaro Muñoz-Abad ,&nbsp;Álvaro Rodríguez-Lescure","doi":"10.1016/j.senol.2024.100633","DOIUrl":"10.1016/j.senol.2024.100633","url":null,"abstract":"<div><div>Triple negative breast cancer (TNBC) accounts for approximately 12%–20% of all breast cancers but usually has a more aggressive clinical course and worse prognosis than hormone receptor expressing breast cancers. Locoregional treatments as well as systemic chemotherapy are part of the therapeutic algorithm in early breast cancer. Currently, neoadjuvant treatment is the standard for TNBC T1c N0 or higher. This strategy allows treating the disease early as well as selecting subsequent adjuvant treatment based on the pathological response achieved. Those patients with early-stage TNBC who have residual disease after completing neoadjuvant therapy have a higher risk of relapse and worse survival than those who achieve pathological complete response. Different drugs (capecitabine, pembrolizumab, olaparib) have so far demonstrated their benefit in the adjuvant setting after previous neoadjuvant treatment without being comparable because their clinical trials differ in design and study population. This scenario is therefore a clinical challenge where the selection criteria are fundamental to identify those patients who can benefit from each of the available therapeutic strategies.</div></div>","PeriodicalId":38058,"journal":{"name":"Revista de Senologia y Patologia Mamaria","volume":"38 1","pages":"Article 100633"},"PeriodicalIF":0.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142357661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Los colgajos de perforantes en la cirugía del cáncer de mama","authors":"Ricardo Pardo Garcia","doi":"10.1016/j.senol.2024.100660","DOIUrl":"10.1016/j.senol.2024.100660","url":null,"abstract":"","PeriodicalId":38058,"journal":{"name":"Revista de Senologia y Patologia Mamaria","volume":"38 1","pages":"Article 100660"},"PeriodicalIF":0.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143161086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary lymphoma of the breast","authors":"Yoldez Houcine ,&nbsp;Nadia Kouki ,&nbsp;Rahma Yaiche ,&nbsp;Salma Kamoun ,&nbsp;Fatma Saadallah ,&nbsp;Maha Driss","doi":"10.1016/j.senol.2024.100631","DOIUrl":"10.1016/j.senol.2024.100631","url":null,"abstract":"<div><h3>Introduction</h3><div>Primary breast lymphoma (PBL) represents a rare form of breast malignancy, with diffuse large B-cell lymphoma (DLBCL) emerging as the predominant histological subtype. Despite advancements, treatment strategies remain contentious.</div></div><div><h3>Objective</h3><div>This study aims to succinctly outline the clinicopathological and immunohistochemical characteristics of PBL while appraising available therapeutic modalities.</div></div><div><h3>Methods</h3><div>Retrospectively, 22 PBL cases from 2003 to 2021 were culled from pathological records at the Salah Azaiez Institute. Immunohistochemistry was employed to discern DLBCL subtypes.</div></div><div><h3>Results</h3><div>Median age stood at 58, with a predominance of 16 female patients over 6 males, notably with over 50% of women being post-menopausal. Clinical manifestation primarily involved a unilateral right-sided breast mass, with concurrent lymph node involvement detected in 10 cases at diagnosis. Radiological data were available for 6 cases, revealing DLBCL as the prevailing pathological subtype in 16 cases (73%). Non-germinal center B-cell type was notably discerned in 9 out of 16 PB-DLBC cases. Treatment modalities encompassed surgery in 5 patients, chemotherapy in 7, and radiotherapy in 3 cases. Among treated individuals, 7 experienced recurrences, 5 of them had DLBCL.</div></div><div><h3>Conclusion</h3><div>Despite its rarity, PBL warrants careful consideration due to its notably aggressive nature, mandating a clear distinction from breast carcinoma owing to differential therapeutic approaches and prognoses. Hence, an accurate diagnosis grounded in thorough pathological and immunohistochemical examination is imperative for tailoring optimal treatment strategies, thereby potentially enhancing outcomes.</div></div>","PeriodicalId":38058,"journal":{"name":"Revista de Senologia y Patologia Mamaria","volume":"38 1","pages":"Article 100631"},"PeriodicalIF":0.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142316224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mastitis granulomatosa con buena respuesta a baricitinib","authors":"Rafael Rubén Pimentel León,&nbsp;Rosa Martha Núñez Rodríguez,&nbsp;María Del Sol Rebollar Vega","doi":"10.1016/j.senol.2024.100651","DOIUrl":"10.1016/j.senol.2024.100651","url":null,"abstract":"<div><div>Granulomatous mastitis is a benign disease of the breast, characterized by the formation of granulomas in the lobules. It occurs in women of reproductive age, commonly with a history of breastfeeding. It is manifested by the formation of abscesses or tumors. For the diagnosis, a biopsy is required and to rule out, in addition to infectious processes, autoimmune diseases. Treatment is controversial, antimicrobials, steroids, immunosuppressants, biological therapy, and surgery have been used. We present the case of a 40-year-old woman with a typical picture of granulomatous mastitis, with failure to the usual therapeutic options, was managed with baricitinib, observing an excellent therapeutic response. There are insufficient data to recommend the use of baricitinib, but it could be considered in the event of standard treatment failure.</div></div>","PeriodicalId":38058,"journal":{"name":"Revista de Senologia y Patologia Mamaria","volume":"38 1","pages":"Article 100651"},"PeriodicalIF":0.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142719651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Distinct salivary antioxidant patterns linked to breast cancer molecular subtypes","authors":"Mariane Fontana Mezoni,&nbsp;Aline Graciele Henriques Campos,&nbsp;Ana Carolina Aredes Goulart,&nbsp;Ana Carolina Lopes Federige,&nbsp;Ana Gabriela de Oliveira Silva,&nbsp;Bruna Yukie Koizumi,&nbsp;Rafaela Oliveira Matos,&nbsp;Felipe da Silva Bender,&nbsp;Gustavo Bendlin Padilha,&nbsp;Victor Pereira da Silva,&nbsp;Rafaella Frederico Almeida,&nbsp;Maria Paula de Andrade Berny,&nbsp;Daniel Rech,&nbsp;Aedra Carla Bufalo,&nbsp;Carolina Panis","doi":"10.1016/j.senol.2024.100634","DOIUrl":"10.1016/j.senol.2024.100634","url":null,"abstract":"<div><h3>Introduction</h3><div>Breast cancer (BC) is a heterogeneous and complex disease characterized by distinct biological subtypes and numerous risk factors. Salivary biomarkers for BC are promising indicators of both oral and systemic health. Given the role of antioxidants in the development and progression of BC, assessing patient's antioxidant capacity through saliva may be a valuable strategy.</div></div><div><h3>Material and methods</h3><div>This study aimed to investigate the antioxidant capacity of saliva in 134 women with BC and its correlation with prognostic factors. Total antioxidant capacity (TRAP) was measured using the high-sensitivity chemiluminescence technique.</div></div><div><h3>Results</h3><div>Significantly reduced salivary TRAP levels were observed in women with tumors positive for estrogen and progesterone receptors (<em>p</em> <!-->&lt;<!--> <!-->.05). Conversely, an increase in salivary TRAP levels was noted in patients with triple-negative tumors. No significant changes were observed in other clinical comparisons. Correlation analysis revealed negative associations between reduced salivary TRAP levels and estrogen receptors (<em>R</em> <!-->=−0.1881) and progesterone receptors (<em>R</em> <!-->=−0.1837). Positive correlations were found between TRAP levels and the ki67 proliferation index above 14% (<em>R</em> <!-->=<!--> <!-->0.1697), as well as the presence of the triple-negative tumor molecular subtype (<em>R</em> <!-->=<!--> <!-->0.2078). Additionally, the analysis showed no correspondence between TRAP levels in saliva and blood, with TRAP levels being higher in blood than in saliva.</div></div><div><h3>Conclusions</h3><div>These findings suggest that salivary TRAP levels could serve as a systemic marker associated with BC, particularly in cases with a worse prognosis, such as triple-negative tumors and high proliferation indices.</div></div>","PeriodicalId":38058,"journal":{"name":"Revista de Senologia y Patologia Mamaria","volume":"38 1","pages":"Article 100634"},"PeriodicalIF":0.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142311292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Carcinomatosis peritoneal secundaria a carcinoma de mama","authors":"Susana Gómez Valmaña ,&nbsp;David Martínez Ramos ,&nbsp;Luis Gómez Quiles ,&nbsp;Jose Manuel Laguna Sastre","doi":"10.1016/j.senol.2024.100608","DOIUrl":"10.1016/j.senol.2024.100608","url":null,"abstract":"<div><div>The incidence of breast cancer is increasing. On the other hand, mortality has decreased in recent years. Increasing survival means that a greater number of recurrences are detected.</div><div>An uncommon and late way of presentation of metastatic disease is at peritoneum. This represents a challenge in management at diagnosis and treatment, given the lack of recommendations and studies in this regard. Therefore, the objective was to carry out a bibliographic review on the latest updates on the diagnostic and therapeutic management of peritoneal carcinomatosis secondary to breast carcinoma and its survival. An exhaustive search has been carried out in different databases on the latest updates on the therapeutic management of peritoneal carcinomatosis in breast cancer. Finally, 31 articles have been included. Breast cancer is the extra-abdominal solid tumor that produces the most peritoneal carcinomatosis and the lobular subtype is the one most associated with this way of dissemination of the disease. The clinical presentation and diagnosis occur usually late, associated with a poor prognosis. The evidence regarding the ideal therapeutic management is scarce, but it has been shown that cytoreduction surgery + HIPEC (hyperthermic intraoperative chemotherapy) presents promising results in selected cases, observing improvement in survival and quality of life of affected patients. Quality prospective studies with a larger sample size are needed to determine the appropriate therapeutic management in peritoneal carcinomatosis due to breast carcinoma.</div></div>","PeriodicalId":38058,"journal":{"name":"Revista de Senologia y Patologia Mamaria","volume":"38 1","pages":"Article 100608"},"PeriodicalIF":0.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142311293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tumores filoides malignos: serie de casos y revisión de la literatura","authors":"Vanesa Rodríguez-Fernández ,&nbsp;Gonzalo José de Castro Parga ,&nbsp;Jorge F. Cameselle-Teijeiro","doi":"10.1016/j.senol.2024.100600","DOIUrl":"10.1016/j.senol.2024.100600","url":null,"abstract":"<div><h3>Introduction</h3><div>Phyllodes tumours (PT) are rare breast tumours with diverse biological behaviour. The purpose of this paper was to conduct a global study of malignant PTs in our healthcare area.</div></div><div><h3>Material and methods</h3><div>A case series study where we reviewed oncological, clinical-diagnostic, therapeutic and prognostic data of malignant PTs diagnosed between 1978 and 2022 in the Vigo area.</div></div><div><h3>Results</h3><div>Out of the total of 64 PTs collected: 40 were benign, 13 borderline and 11malignant. The mean age of the total PT series was 49.8 years, with no differences being found between categories. All the malignant PTs in our series were in women who consulted for breast lumps. Mean size was 8 cm (2.5-20 cm). With regard to type of surgery, there were 6 cases of mastectomy and 4 cases of conservative surgery, one lymphadenectomy without apparent indication and without metastatic involvement. Radiotherapy was received in only one case, and in another adjuvant hormone therapy was received. Regarding prognostic evolution, one case presented local recurrence (4 years after surgery) and two cases developed metastasis (which was the cause of death after 1.5 and 8 years).</div></div><div><h3>Conclusions</h3><div>Malignant PTs are a rare entity. This was a historical series of only 11 patients. Surgical excision (margins ≥ 1 cm) without lymphadenectomy is the treatment of choice. Radiotherapy was effective in reducing local recurrences, but chemotherapy and hormone therapy are not substantiated. Suspected diagnosis is important to reduce associated morbidity and mortality and further studies are required to guide clinical practice.</div></div>","PeriodicalId":38058,"journal":{"name":"Revista de Senologia y Patologia Mamaria","volume":"38 1","pages":"Article 100600"},"PeriodicalIF":0.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142319598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Potencial papel de la tomografía por emisión de positrones con fluorodesoxiglucosa (18F-FDG PET/TC) en la estadificación inicial del cáncer de mama","authors":"Rocío Sánchez Sánchez ,&nbsp;Antonio Daniel González Jiménez ,&nbsp;Tariq Aroui Luquin ,&nbsp;Inmaculada Mendoza Arnau ,&nbsp;Isabel Pérez Herrezuelo","doi":"10.1016/j.senol.2024.100629","DOIUrl":"10.1016/j.senol.2024.100629","url":null,"abstract":"<div><h3>Objective</h3><div>Multiple studies have evaluated the usefulness of ¹⁸F-FDG-PET/CT in the initial staging of breast cancer, demonstrating an important clinical impact with a change in therapeutic management. However, its role in current clinical practice is controversial and its use remains optional for major guidelines. Our objective is to assess the usefulness of PET/CT in this context.</div></div><div><h3>Material and method</h3><div>The results of PET/CT in patients recently diagnosed with breast cancer (2021–2022) have been analyzed visually and semiquantitatively using SUVmax. Positive findings were confirmed by specific imaging procedures.</div></div><div><h3>Results</h3><div>We prospectively evaluated 166 patients (59.8 ± 12.08 years). The primary tumor was detected by PET/CT in all cases. At diagnosis, 58 patients had axillary lymph node involvement by PET/CT. Axillary ultrasound detected lymph node involvement in 79% (46/58). Furthermore, in the 46 patients with lymph node involvement detected by both tests, PET/CT increased the number of lymph node lesions, thus modifying the stage. Unsuspected distant metastases were diagnosed by PET/CT in 12 patients, 10 had axillary lymph node involvement. The variables significantly associated with a higher probability of axillary or distant metastases in PET/CT were: histological grade 2–3 (<em>p</em> = 0.03), elevated Ki67 (<em>p</em> = 0.002) and higher SUVmax of the primary lesion (<em>p</em> = 0.02).</div></div><div><h3>Conclusions</h3><div>Our results suggest a potential usefulness of PET/CT in the initial staging of patients with breast cancer, particularly in those with axillary involvement, for the detection of unsuspected distant metastases.</div></div>","PeriodicalId":38058,"journal":{"name":"Revista de Senologia y Patologia Mamaria","volume":"38 1","pages":"Article 100629"},"PeriodicalIF":0.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142319599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimización del diagnóstico y estadificación TNM del cáncer de mama en acto único desde el servicio de radiología: protocolo TEMA","authors":"Florentina Guzmán-Aroca,&nbsp;Ana Azahara García-Ortega,&nbsp;Josefa Pérez-Templado,&nbsp;Juan Francisco Martínez-Martínez,&nbsp;Francisco Sarabia-Tirado,&nbsp;José Luis Alonso-Romero,&nbsp;Antonio Piñero-Madrona","doi":"10.1016/j.senol.2024.100610","DOIUrl":"10.1016/j.senol.2024.100610","url":null,"abstract":"<div><h3>Introduction</h3><p>After histological confirmation, mammography, ultrasound (including nodal territory), and MRI are used for locoregional staging. Tests such as computed tomography (CT) are used for the study of distant metastases.</p></div><div><h3>Methods</h3><p>Prospective randomized controlled study with 44 patients (September 2022 to March 2023), studied by initial directed ultrasound with: breast nodules suspicious for malignancy (BNSM) &gt;<!--> <!-->5 cm or associated breast inflammation, BNSM with lymphadenopathy (axillary/internal mammary region), or lymphadenopathy in axillary/internal mammary region without nodule. Half followed the usual protocol and the other half the TEMA protocol (thoraco-abdominal-pelvic CT and mammography with contrast with the same bolus of intravenous contrast, 2 phases, tomosynthesis and ultrasound with biopsies; all in a single act).</p></div><div><h3>Results</h3><p>There were no significant differences in age, stage, tumor type, or immunophenotype between the two groups. With the usual protocol, the mean time from biopsy of lesions with suspected malignancy to staging CT scan, or Total Delay Time (TDT) was 40 days, and all had started neoadjuvant chemotherapy. The median time required for diagnóstico and staging with the TEMA protocol was 27 min.</p></div><div><h3>Conclusions</h3><p>Initial targeted ultrasound identifies patients who will benefit from initial locoregional and distant staging, candidates for the TEMA protocol. This allows immediate complete staging, which is more accurate (without modifications due to chemotherapy), and eliminating TDT.</p></div>","PeriodicalId":38058,"journal":{"name":"Revista de Senologia y Patologia Mamaria","volume":"37 4","pages":"Article 100610"},"PeriodicalIF":0.3,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141951550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tumor phyllodes maligno asociado a carcinoma ductal infiltrante de la mama, descripción de un caso tratado en nuestro centro","authors":"María Valvanera Garcia Moreno,&nbsp;Claudia Bagur Bagur,&nbsp;Fernando Alcaide Matas","doi":"10.1016/j.senol.2024.100612","DOIUrl":"10.1016/j.senol.2024.100612","url":null,"abstract":"<div><p>The association of Phyllodes tumor with malignant epithelial neoplasms is very rare, which is why the presentation of a case recently treated in our unit is of interest. This article describes our experience in the diagnosis and treatment of a 72-year-old patient diagnosed with a Phyllodes tumor of the breast associated with a triple-negative infiltrating ductal carcinoma and aims to draw attention to this very rare association. The association of Phyllodes tumor and carcinoma occurs in only 1–2% of all phyllodes tumors. Types of carcinomas include carcinoma <em>in situ</em>, invasive forms ductal, lobular, tubular and squamous carcinoma, with the ductal phenotype being the most frequently related usually located inside or adjacent to the phyllodes tumor, since the carcinoma originates from the epithelial component of this tumor. Detecting the carcinomatous component prior to surgical intervention is very difficult, being diagnosed in most cases in the definitive pathological study. The main treatment is surgery with wide margins, sometimes combining SLNB, if it is associated with a carcinoma. A detailed analysis of tumor characteristics with reference to molecular subtype and pathological features should be performed to select the optimal treatment strategy for Phyllodes tumor-associated carcinoma.</p></div>","PeriodicalId":38058,"journal":{"name":"Revista de Senologia y Patologia Mamaria","volume":"37 4","pages":"Article 100612"},"PeriodicalIF":0.3,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141951551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}